Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

National Institute for Health Care Research

- PMLiVE

NHS patients to access Theramex’s endometriosis pill following NICE recommendation

The once-a-day drug has been recommended for patients with a history of previous medical or surgical treatment

- PMLiVE

NICE recommends Theramex’s Eladynos to treat bone disease after menopause

Osteoporosis, which particularly impacts older women after menopause, currently affects 3.8 million people in the UK

- PMLiVE

Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis

More than ten million adults in the US alone over the age of 50 are estimated to have the condition

- PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year

- PMLiVE

UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

First new drug for the disease in the EU since 2010

- PMLiVE

Amgen and UCB’s Evenity finally approved, but with label warnings

Drug unlikely to match Prolia's revenues

- PMLiVE

Evenity back on track with FDA panel blessing in osteoporosis

US drugs regulator first rejected the drug due to cardiovascular concerns

Osteoporosis

Cuttsy+Cuttsy launch their latest patient e-book

On the eve of ‘World Osteoporosis Day’ (worldosteoporosisday.org), Cuttsy+Cuttsy are proud to launch their latest e-book ‘Osteoporosis…in plain English’.

Cuttsy + Cuttsy

- PMLiVE

ViiV’s two-drug HIV combo backed by CHMP

The committee also backs two biosimilar medicines

- PMLiVE

FDA rejects Amgen’s osteoporosis hope romosozumab

Its partner UCB plans to submit the medicine for European approval later this year

- PMLiVE

Amgen’s Kyprolis scarred by head-to-head duel with Velcade

Failed to show superior progression-free survival in first-line treatment trials

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links